A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Clinical trial NCT05005442 · COMPLETED

Trial details

NCT number: NCT05005442
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hematological Malignancies

Start date: 2021-09-28
Primary completion: 2024-12-10
Enrollment: 192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.